Medicare GLP-1 Bridge: The $50/Month Program Fact-Checked

The Medicare GLP-1 Bridge has generated excitement — and confusion. Here's what the CMS announcement actually says, sourced directly from official documents.

What It Is

A time-limited demonstration program from CMS providing eligible Medicare Part D beneficiaries access to select GLP-1 medications at $50/month. It operates outside the standard Part D benefit structure.

Timeline

July 1, 2026 through December 31, 2027 (18 months). CMS has indicated the program could inform longer-term coverage decisions.

Covered Medications

All doses and formulations of Wegovy are included. Novo Nordisk confirmed coverage for both injectable and oral pill formulations.

Eligibility

Enrolled in Medicare Part D or Medicare Advantage with drug coverage. BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (heart disease, prediabetes, hypertension, high cholesterol, sleep apnea, among others). Must have a prescription from a licensed provider.

Cost Structure

Participating manufacturers provide medications at approximately $245/month net price. Beneficiaries pay approximately $50 per monthly prescription. The program does not affect standard Part D deductibles or catastrophic coverage thresholds.

What It Doesn't Cover

The Bridge program is specifically for weight management. Patients already receiving GLP-1 coverage for diabetes, cardiovascular disease, or other FDA-approved indications continue through standard Part D benefits.